MIRM: Mirum Pharmaceuticals Inc

MIRM新闻

• 15:02 TD Cowen维持对Mirum Pharmaceuticals的买入评级，将目标价上调至145美元
• 15:02 TD Cowen Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $145
• 14:04 Stifel Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $156
• 17:51 Evercore ISI Group Maintains Outperform on Mirum Pharmaceuticals, Raises Price Target to $146
• 17:51 Evercore ISI集团维持对Mirum Pharmaceuticals的“跑赢大盘”评级，将目标股价上调至146美元
• 13:41 Mirum's Livmarli Meets Phase III Goal in Ultra-Rare Liver Diseases
• 10:04 Morgan Stanley Maintains Overweight on Mirum Pharmaceuticals, Raises Price Target to $152
• 21:02 Citigroup Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $184
• 21:02 花旗维持对 Mirum Pharmaceuticals 的买入评级，将目标价上调至 184 美元
• 17:09 HC Wainwright & Co. Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $200
• 17:09 HC Wainwright & Co. 维持对 Mirum Pharmaceuticals 的“买入”评级，将目标价上调至 200 美元
• 16:42 Mirum Pharmaceuticals, Inc. (MIRM) Discusses Phase 3 EXPAND Study Results for Maralixibat in Cholestatic Pruritus Including Biliary Atresia Transcript
• 14:23 Mirum Pharmaceuticals, Inc. (MIRM) Discusses Phase 3 EXPAND Study Results for Maralixibat in Cholestatic Pruritus Including Biliary Atresia - Slideshow (NASDAQ:MIRM) 2026-10-12
• 13:38 Why Is Mirum Pharmaceuticals Stock Gaining Monday?
• 12:05 12 Health Care Stocks Moving In Monday's Pre-Market Session
• 12:05 Mirum Pharmaceuticals' Phase 3 EXPAND Study Evaluating LIVMARLI Meets Primary Endpoint, Achieves Statistical Significance Across All Secondary Endpoints
• 10:42 What to Expect From Incyte’s Next Quarterly Earnings Report
• 14:55 RBC资本维持对Mirum Pharmaceuticals的“跑赢大盘”评级，将目标价上调至155美元
• 14:55 RBC Capital Maintains Outperform on Mirum Pharmaceuticals, Raises Price Target to $155
• 17:56 Citigroup Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $160